Hyung C. Suh

Hackensack University Medical Center — United States

Medicine · Health Sciences

14h-index920citations67works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(24), CAR-T cell therapy research(21), Hematopoietic Stem Cell Transplantation(17), Acute Lymphoblastic Leukemia research(8), Chronic Lymphocytic Leukemia Research(8)

Publications67 total

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma
Blood·2025· 1 citedOpen Access
Remission of <i>TP53</i> -Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)
JCO Precision Oncology·2025
Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia
Transplantation and Cellular Therapy·2025· 2 cited
Peripheral blood cell-free DNA testing as a predictor for relapse post-allogeneic stem cell transplant for AML.
Journal of Clinical Oncology·2025
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
Nature Medicine·2025· 22 citedOpen Access
Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases
Cancers·2025Open Access
cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies
Cancers·2025· 1 citedOpen Access
A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
Transplantation and Cellular Therapy·2025
TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)
Transplantation and Cellular Therapy·2025· 1 cited
Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study
Hemato·2025· 1 citedOpen Access
A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
Blood·2024· 2 citedOpen Access
Potential Role of Donor CD3 Chimerism in Predicting Relapse after Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia (AML)
Blood·2024
TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
Blood·2024· 2 citedOpen Access
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in &lt;i&gt;de novo&lt;/i&gt; large B-cell lymphoma and transformed low-grade B-cell lymphoma
Haematologica·2024· 4 citedOpen Access
A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
Journal of Clinical Oncology·2024· 1 cited
Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).
Journal of Clinical Oncology·2024
Abstract CT151: Trial in progress:A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation
Cancer Research·2024
Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation
Cancers·2024· 7 citedOpen Access
Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).
Transplantation and Cellular Therapy·2024· 6 cited
TSC-100 and TSC-101, TCR-T Cell Therapies That Target Residual Recipient Cells after Reduced Intensity Conditioning Transplantation, Induce Complete Donor Chimerism with Favorable Prognosis: Early Results of a Phase 1 Trial
Transplantation and Cellular Therapy·2024· 5 cited
page 1 of 4Next →

Frequent Co-authors

Michèle L. Donato(13), Scott D. Rowley(13), Sukhdeep Kaur(11), Andrew Ip(10), Jonathan R. Keller(8), Miguel‐Angel Perales(7), Nirali N. Shah(7), John F. DiPersio(7), Divya Koura(7), Guenther Koehne(7), Kimberly D. Klarmann(6), Melissa Baker(6), André Goy(6), Lori A. Leslie(6), Sritama Nath(6), Shrikanta Chattopadhyay(6), Ran Reshef(6), John Gooya(5), Phyllis McKiernan(5), Michele Boonstra(5)